english

Lundi 19 Novembre 2018, 14h00

Sylvie Mader, IRIC, Montréal, Qc, Canada

 

"Estrogen signalling and its inhibition for breast cancer treatment"

 

Contact: marie-alix.poul@inserm.fr

 

After training in France at Ecole Normale Supérieure de Paris, Université Paris VI and Institut Pasteur, Sylvie Mader joined the team of Professor Pierre Chambon in Strasbourg for a Ph.D. in Biochemistry at the Laboratoire de Génétique Moléculaire des Eucaryotes, during which she characterized the mechanisms of target gene regulation by nuclear receptors. She then trained as a postdoctoral fellow with Professor Nahum Sonenberg at the Biochemistry department at McGill University, where she uncovered a mechanism of translational control involving formation of competitive complexes with the translation intiation factor eIF4E. Sylvie Mader put together her research team at Université de Montréal in 1995, with a focus on the therapeutic modulation of molecular signaling pathways involved in breast cancer.  Since joining IRIC in 2005, Sylvie Mader and her team use cutting-edge technologies such as functional genomics, proteomics, bioinformatics and biophysics to identify novel therapeutic targets and design new drugs for breast cancer treatment. In particular, her team is studying nuclear receptor signaling pathways, which are attractive targets for drug development. She is also analyzing the mechanisms of mammary cell differentiation and tumorigenesis in cultured cells and animal models.

Vendredi 7 décembre 2018, 14h00

Paul Hofman

 

IRCAN, U1081, NICE

 

"circulating tumor cells detection in lung cancer: What’s for?"

 

contact: antonio.maraver@inserm.fr

Vendredi 14 décembre 2018, 14H

Sylvain Méloche

 

IRIC, Université de Montréal, Qc, Canada

 

"Identification and preclinical validation of new therapeutic targets in liver cancer."

 

Contact: marie-alix.poul@inserm.fr

Vendredi 11 janvier 2019, 14h

Camille Lobry

 

Normal and cancerous Haematopoietic stem cells: genetic and epigenetic control, Gustave Roussy, Villejuif

 

"CRISPRi-based screening of clustered regulatory elements reveals novel cancer dependencies"

 

contact: antonio.maraver@inserm.fr

Mercredi 13 Février 2019, 14h; SIRIC Cancer Highlight Seminar

Sophie Lelièvre, Purdue University Center for Cancer Research, West Lafayette, In. USA

 

“Cancer-on-a-chip to study progression mechanisms and anticancer drug sensitivity”

 

Contact: charles.theillet@inserm.fr

 

SUMMARY:
The design of tissue-chips is gaining momentum because these engineered cell culture platforms provide highly controlled microenvironments for the study of normal and diseased tissues. I will discuss how tissue-chips can be used to recreate the organ geometry necessary for the full recapitulation of cell behavior, using the example of carcinomas that develop within ducts. Indeed, the curved environment of hemichannels confers mechanical constraints that influence drug sensitivity. So far, this system is surpassing other cell culture models for the assessment of drug efficacy at the cancer cell level, as shown with the example of triple negative breast cancer. Another use of tissue-chips is to create gradients of molecules in the microenvironment that are conducive to tissue heterogeneity responsible for cancer progression and drug resistance. We have designed a gradient-on-a-chip with which we demonstrated that increased matrix stiffness associated with breast cancer progression lowers the concentration at which progression promoting oxidizing molecules worsen cancer phenotypes. Throughout the seminar basic principles of tissue-chip design will be presented and the applications of cancers-on-a-chip for precision medicine will be highlighted.

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés